4/A: OptimizeRx Executive Corrects Stock Grant Date and Ownership in Amended SEC Filing

Stephen L. Silvestro, Chief Commercial Officer of OptimizeRx Corp, files an amended Form 4 to correct the grant date of common stock and adjust the number of beneficially owned shares.

Summary

• Stephen L. Silvestro, Chief Commercial Officer of OptimizeRx Corp, filed an amended Form 4 with the SEC.
• The amendment corrects the date of a common stock grant from March 15, 2024, to February 15, 2024.
• It also adjusts the number of shares beneficially owned to rectify an understatement in a previous filing.
• Silvestro was granted 7,750 restricted stock units on February 15, 2024, which will vest on February 15, 2025.
• Following the reported transactions, Silvestro beneficially owns 16,906 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral. It's a routine correction of a filing, indicating standard corporate governance procedures are being followed. The correction of the error is a positive sign.

Negatives

• A previous Form 4 filing contained an error, understating the number of shares beneficially owned by the reporting person.

Industry Context

Form 4 filings are standard practice for company insiders to report transactions in their company's stock, ensuring transparency and compliance with SEC regulations.

Stakeholder Impact

• The correction of the filing ensures accurate information is available to shareholders and potential investors.

Key Dates